Metabolism of apolipoprotein C-III in normolipemic human subjects. 1988

C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
Research Foundation on Atherosclerosis, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.

Radioiodinated apolipoprotein C-III labeled either by the iodine monochloride procedure or by the Bolton-Hunter reagent were incubated in vitro with normal HDL. The labeled HDL-apo C-III, after ultracentrifugation and dialysis, was injected intravenously in 8 normolipidemic subjects. The label was followed in VLDL, IDL + LDL, HDL, d = 1.225 g/ml infranate as well as in total plasma and urine for the first time over a period of 2 weeks. Apolipoprotein C-III distributes readily between the different lipoprotein classes, only a small amount being present in the non-lipoprotein fraction. The percent distribution of apo C-III radioactivity and mass was found similar in VLDL, IDL and HDL using 3 different separation methods. Residence time in the whole system was 2.45 +/- 0.33 days. Fractional catabolic rates calculated from the urine/plasma radioactivity ratios or from the plasma curve were 0.731 +/- 0.096 and 0.767 +/- 0.125 pools/day. Synthetic rate was 2.28 +/- 0.32 mg/day/kg. The parameters seem not affected by the labeling procedure. The shapes of the plasma curve and of the urine/plasma ratio curve suggest a kinetic heterogeneity in the metabolism of apo C-III-containing particles.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008079 Lipoproteins, VLDL A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues. Pre-beta-Lipoprotein,Prebeta-Lipoprotein,Prebeta-Lipoproteins,Very Low Density Lipoprotein,Very-Low-Density Lipoprotein,Very-Low-Density Lipoproteins,Lipoprotein VLDL II,Lipoproteins, VLDL I,Lipoproteins, VLDL III,Lipoproteins, VLDL1,Lipoproteins, VLDL2,Lipoproteins, VLDL3,Pre-beta-Lipoproteins,Lipoprotein, Very-Low-Density,Lipoproteins, Very-Low-Density,Pre beta Lipoprotein,Pre beta Lipoproteins,Prebeta Lipoprotein,Prebeta Lipoproteins,VLDL Lipoproteins,VLDL1 Lipoproteins,VLDL2 Lipoproteins,VLDL3 Lipoproteins,Very Low Density Lipoproteins
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D005260 Female Females

Related Publications

C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
November 1991, The Journal of clinical investigation,
C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
January 2000, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia,
C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
June 2011, Journal of lipid research,
C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
March 1986, FEBS letters,
C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
June 1990, Journal of lipid research,
C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
June 2018, Current opinion in lipidology,
C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
November 1984, Journal of lipid research,
C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
February 2001, Nihon rinsho. Japanese journal of clinical medicine,
C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
January 1982, Journal of postgraduate medicine,
C L Malmendier, and J F Lontie, and G A Grutman, and C Delcroix
January 1985, Metabolism: clinical and experimental,
Copied contents to your clipboard!